Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults

Vaccine

Volumn 30, Issue 49, 2012, Pages 7067-7071

  Nielsen, Allan Bybeck ^a   Nielsen, Henriette Schjønning ^b   Nielsen, Lars ^b   Thybo, Søren ^c   Kronborg, Gitte ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

HIV infection; Immune response; Pandemic influenza A (H1N1); Vaccination

Indexed keywords

AS03 VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; SINGLE DRUG DOSE;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; SQUALENE;

EID: 84869086842     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.052     Document Type: Article

References (43)

1. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
2. Cohen J.P., Macauley C. Susceptibility to influenza A in HIV-positive patients. JAMA 1989, 261:245.
3. Fine A.D., Bridges C.B., De Guzman A.M., Glover L., Zeller B., Wong S.J., et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 2001, 32:1784-1791.
4. Boschini A., Longo B., Caselli F., Begnini M., De Maria C., Ansaldi F., et al. An outbreak of influenza in a residential drug-rehabilitation community. J Med Virol 2006, 78:1218-1222.
5. Radwan H.M., Cheeseman S.H., Lai K.K., Ellison I.R. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000, 31:604-606.
6. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
7. Neuzil K.M., Coffey C.S., Mitchel E.F., Griffin M.R. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003, 34:304-307.
8. Klein M.B., Lu Y., DelBalso L., Coté S., Boivin G. Clin Infect Dis 2007, 45:234-240.
9. Martínez E., Marcos M.A., Hoyo-Ulloa I., Antón A., Sánchez M., Vilella A., et al. Influenza A H1N1 in HIV-infected adults. HIV Med 2011, 12:236-245.
10. Campos-Loza A., Soto-Ramirez L., Sierra-Madero J., Crabtree-Ramírez B., Galindo-Fraga A., Moreno-Espinosa S., et al. New swine origin influenza A in HIV-infected patients during the 2009 outbreak in Mexico City [abstract]. 17th conference on retroviruses and opportunistic infections 2010, 801. Available at: http://www.retroconference.org/2010/PDFs/801.pdf [accessed 01.05.12].
11. Isais F., Lye D., Llorin R., Dimatatac F., Go C.J., Leo Y.S., et al. Pandemic (H1N1) 2009 influenza in HIV infected adults: clinical features severity and outcome. J Infect 2010, 61:437-440.
12. Archer B., Cohen C., Naidoo D., Thomas J., Makunga C., Blumberg L., et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009, 14. pii:19369.
13. Ormsby C.E., de la Rosa-Zamboni D., Vázquez-Pérez J., Ablanedo-Terrazas Y., Vega-Barrientos R., Gómez-Palacio M., et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 2011, 25:435-439.
14. Mølbak K., Widgren K., Jensen K.S., Ethelberg S., Andersen P.H., Christiansen A.H., et al. Burden of illness of the 2009 pandemic of influenza A (H1N1) in Denmark. Vaccine 2011, 29(Suppl. 2):B63-B69.
15. WHO influenza reagent kit for identification of influenza isolates 2010-2011, WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Centers for Disease Control and Prevention, Available at: http://www.influenzareagentresource.org/WHOKitForms.aspx [accessed 01.05.12].
16. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
17. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
18. Durando P., Fenoglio D., Boschini A., Ansaldi F., Icardi G., Sticchi L., et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008, 15:253-259.
19. Schultze V., D'Agosto V., Wack A., Novicki D., Zorn J., Hennig R. Safety of MF59 adjuvant. Vaccine 2008, 26:3209-3222.
20. Banzhoff A., Nacci P., Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003, 49:177-184.
21. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.-K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
22. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
23. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
24. Stephenson I., Heath A., Major D., Newman R.W., Hoschler K., Junzi W., et al. Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis 2009, 15:1252-1329.
25. European Committee for Proprietary Medicinal Products (CHMP) Guideline on influenza vaccine prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context (EMEA/CHMP/VWP/263499/2006) 2007, European Agency for the Evaluation of Medicinal Products, Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003872.pdf [accessed 01.05.12].
26. US Food and Drug Administration (FDA) Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines 2007, US Food and Drug Administration, Available at: http://www.fda.gov/cber/gdlns/panfluvac.htm [accessed 01.05.12].
27. Ferguson M., Risi G., Davis M., Sheldon E., Baron M., Li P., et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012, 205:733-744.
28. Calmy A., Bel M., Nguyen A., Combescure C., Delhumeau C., Meier S., et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med 2012, 13:207-218.
29. Launay O., Desaint C., Durier C., Loulergue P., Duval X., Jacomet C., et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011, 204:124-134.
30. Orlando G., Pariani E., Mazza F., Tanzi E., Meraviglia P., Gianelli E., et al. Pandemic influenza vaccine in adult HIV-1-infected patients. AIDS 2010, 24:2142-2143.
31. Soonawala D., Rimmelzwaan G.F., Gelinck L.B., Visser L.G., Kroon F.P. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 2011, 6:e16496.
32. Manuel O., Pascual M., Hoschler K., Giulieri S., Alves D., Ellefsen K., et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011, 52:248-256.
33. Cooper C., Klein M., Walmsley S., Haase D., MacKinnon-Cameron D., Marty K., et al. High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1 (2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials 2012, 13:23-32.
34. Kajaste-Rudnitski A., Galli L., Nozza S., Tambussi G., Di Pietro A., Pellicciotta G., et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011, 25:177-183.
35. Bickel M., von Hentig N., Wieters I., Khaykin P., Nisius G., Haberl A., et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis 2011, 52:122-127.
36. Fabbiani M., Di Giambenedetto S., Sali M., Farina S., Sansonetti P., Tamburrini E., et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011, 29:2836-2839.
37. Yanagisawa N., Maeda K., Ajisawa A., Imamura A., Suganuma A., Ando M., et al. Reduced immune response to influenza A (H1N1) 2009 monovalent vaccine in HIV-infected Japanese subjects. Vaccine 2011, 29:5694-5698.
38. Tebas P., Frank I., Lewis M., Quinn J., Zifchak L., Thomas A., et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010, 24:2187-2192.
39. Crum-Cianflone N.F., Eberly L.E., Duplessis C., Maguire J., Ganesan A., Faix D., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011, 52:138-146.
40. Tremblay C.L., Rouleau D., Fortin C., Toma E., Sylla M., Cyr L., et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine 2011, 29:1359-1363.
41. El Sahly H.M., Davis C., Kotloff K., Meier J., Winokur P.L., Wald A., et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis 2012, 205:703-712.
42. Crum-Cianflone N.F., Iverson E., Defang G., Blair P.J., Eberly L.E., Maguire J., et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 2011, 29:3183-3191.
43. Emborg H.D., Krause T.G., Hviid A., Simonsen J., Mølbak K. Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10. BMJ 2011, 344:d7901.